- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Philips Enters North American Mammo Market with New System
Given concerns about radiation dose and a call for more comfortable machines, officials at Philips saw an opportunity for a new product in the North American mammography market. Last week Philips introduced their MicroDose Mammography system, which officials said provides a lower dose, less stressful scan.
Given concerns about radiation dose and a call for more comfortable machines, officials at Philips saw an opportunity for a new product in the North American mammography market. Last week Philips introduced their MicroDose Mammography system, which officials said provides a lower dose, less stressful scan.
“The U.S. is in the process of turning over the generation one machines to a purchase cycle, so we believe this is the perfect product” for the market, said Pam Benkert, general manager, women’s healthcare for Philips Healthcare. “We wanted a differentiated offering.”
MicroDose is the only FDA-cleared mammography system to use X-ray photon counting technology. The detector captures almost every photon that travels from the source to the breast to the detector, Benkert explained. There’s very little scatter, which allows for an up to 50 percent dose reduction, she said.
The machine also has curved support and a warm position surface, intended to make it more comfortable for the patient, she said.
The product, she said, is “uniquely suited to the population” in North America.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
